Immunotherapy shows promise against oral precancer in small trial
NCT ID NCT02882282
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This phase 2 study tested whether the immunotherapy drug pembrolizumab could help people with high-risk oral precancer (oral intraepithelial neoplasia) avoid developing invasive oral cancer. Fifteen participants were randomly assigned to receive pembrolizumab or be observed without treatment. The goal was to see if the drug could improve cancer-free survival and overall survival by helping the immune system attack abnormal cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL CAVITY CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.